Thromboembolic Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Thromboembolic Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Thromboembolism is a condition in which a a thrombus (blood clot) detaches and blocks the blood vessel (embolizes). Venous thromboembolism can lead to two types of conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). Risk factors that contribute to VTE are injury to vein, infection, immobilization, high estrogen, smoking, obesity, age, chronic illness, and blood clotting conditions. Signs and symptoms include swelling, redness, pain, shortness of breath, tachycardia, tachypnea, and sweating. A thromboembolism is diagnosed by vascular ultrasound, MR venography, contrast venography, pulse oximetry, chest x-ray, and pulmonary angiogram. Treatment options include warfarin, heparin, and low molecular weight heparin (LMWH).
The Thromboembolic Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Thromboembolic Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolic Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Thromboembolic Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 6 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Thromboembolic Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Thromboembolic Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Thromboembolic Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
HEC Pharma Co LtdHefei Medical & Pharmaceutical Co Ltd
Ionis Pharmaceuticals Inc
Prothix BV
Sichuan Kelun Pharmaceutical Co Ltd
University of Queensland
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Thromboembolic Disease reports